BR112015023483B8 - Uso de um inibidor de b-raf e um inibidor de mek 1/2" - Google Patents

Uso de um inibidor de b-raf e um inibidor de mek 1/2"

Info

Publication number
BR112015023483B8
BR112015023483B8 BR112015023483A BR112015023483A BR112015023483B8 BR 112015023483 B8 BR112015023483 B8 BR 112015023483B8 BR 112015023483 A BR112015023483 A BR 112015023483A BR 112015023483 A BR112015023483 A BR 112015023483A BR 112015023483 B8 BR112015023483 B8 BR 112015023483B8
Authority
BR
Brazil
Prior art keywords
inhibitor
raf
raf inhibitor
resistance
genetic alterations
Prior art date
Application number
BR112015023483A
Other languages
English (en)
Other versions
BR112015023483A8 (pt
BR112015023483A2 (pt
BR112015023483B1 (pt
Inventor
Caponigro Giordano
Stuart Darrin
De Parseval Laure
Original Assignee
Novartis Ag
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50439443&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015023483(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Array Biopharma Inc filed Critical Novartis Ag
Publication of BR112015023483A2 publication Critical patent/BR112015023483A2/pt
Publication of BR112015023483A8 publication Critical patent/BR112015023483A8/pt
Publication of BR112015023483B1 publication Critical patent/BR112015023483B1/pt
Publication of BR112015023483B8 publication Critical patent/BR112015023483B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

COMBINAÇÕES DE FÁRMACOS COMPREENDENDO UM INIBIDOR DE B-RAF E UM SEGUNDO INIBIDOR, SEUS USOS, E KIT DIAGNÓSTICO. A presente invenção refere-se à reversão da resistência a um inibidor de B-Raf para o tratamento de uma doença proliferativa, obtendo uma amostra do tumor do paciente e testando-a para alterações genéticas em um painel de genes compreendendo BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3 EGFR, MAP2K1, MAP2K2, NRAS, KRAS HRAS, PTEN, PIK3CA, e P16 e administração de uma terapia de combinação de medicamentos que compreende o inibidor de B-Raf e um segundo inibidor que supera a resistência ao inibidor de B-Raf, na qual o segundo inibidor é selecionado com base em alterações genéticas, descobertas na amostra do tumor.
BR112015023483A 2013-03-21 2014-03-19 Uso de um inibidor de b-raf e um inibidor de mek 1/2" BR112015023483B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361804056P 2013-03-21 2013-03-21
US61/804,056 2013-03-21
PCT/IB2014/059975 WO2014147573A2 (en) 2013-03-21 2014-03-19 Combination therapy

Publications (4)

Publication Number Publication Date
BR112015023483A2 BR112015023483A2 (pt) 2017-07-18
BR112015023483A8 BR112015023483A8 (pt) 2019-12-03
BR112015023483B1 BR112015023483B1 (pt) 2022-07-19
BR112015023483B8 true BR112015023483B8 (pt) 2023-01-31

Family

ID=50439443

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023483A BR112015023483B8 (pt) 2013-03-21 2014-03-19 Uso de um inibidor de b-raf e um inibidor de mek 1/2"

Country Status (34)

Country Link
US (3) US9913844B2 (pt)
EP (1) EP2976106B1 (pt)
JP (2) JP6449234B2 (pt)
KR (2) KR102258698B1 (pt)
CN (2) CN105209073A (pt)
AR (1) AR095699A1 (pt)
AU (1) AU2014233805B2 (pt)
BR (1) BR112015023483B8 (pt)
CA (1) CA2907704C (pt)
CL (2) CL2015002807A1 (pt)
CY (1) CY1124776T1 (pt)
DK (1) DK2976106T3 (pt)
EA (1) EA201591842A1 (pt)
ES (1) ES2870716T3 (pt)
GT (1) GT201500249A (pt)
HK (1) HK1214135A1 (pt)
HU (1) HUE055072T2 (pt)
IL (2) IL241188B (pt)
JO (1) JOP20140128B1 (pt)
MA (2) MA44934B1 (pt)
MX (1) MX2015013466A (pt)
MY (1) MY181085A (pt)
NZ (1) NZ712184A (pt)
PE (1) PE20151785A1 (pt)
PH (1) PH12015502040A1 (pt)
PL (1) PL2976106T3 (pt)
PT (1) PT2976106T (pt)
SG (2) SG11201507730UA (pt)
SI (1) SI2976106T1 (pt)
TN (1) TN2015000389A1 (pt)
TW (1) TWI603734B (pt)
UA (1) UA118846C2 (pt)
WO (1) WO2014147573A2 (pt)
ZA (1) ZA201800424B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014233805B2 (en) 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor
JP2017517558A (ja) * 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 癌薬剤耐性の治療方法及び防止方法
CN105753869B (zh) * 2015-04-01 2018-09-25 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
PL3283058T3 (pl) * 2015-04-16 2023-03-20 Novartis Ag Tabletka rybocyklibu
US9814714B2 (en) * 2015-05-22 2017-11-14 Plexxikon Inc. Kinase modulation, and indications therefor
CN105732642B (zh) * 2015-11-18 2018-09-25 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
CA3013845A1 (en) * 2016-02-19 2017-08-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of pik3ca-related overgrowth spectrum
CR20190002A (es) 2016-06-03 2019-06-10 Zhu Alexander Cao Combinaciones farmacéuticas
CN107058565A (zh) * 2016-08-31 2017-08-18 郭军 肢端型黑色素瘤的诊断和治疗
BR112019005046A2 (pt) * 2016-09-19 2019-06-18 Novartis Ag combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk
EP3559276B1 (en) 2016-12-20 2022-03-23 ETH Zurich Identification of drugs targeting non-genetic drug tolerance programs in cancer
WO2018213302A1 (en) * 2017-05-16 2018-11-22 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
WO2018218633A1 (en) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
WO2023212071A1 (en) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Combination and the use thereof
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2023240178A1 (en) * 2022-06-08 2023-12-14 Mapkure, Llc Methods of treating cancer with a b-raf inhibitor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2275102E (pt) * 2002-03-13 2015-10-27 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
TW200406203A (en) 2002-03-13 2004-05-01 Array Biopharma Inc N3 alkylated banzimidazole derivatives as MEK inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005051301A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20060134068A1 (en) 2004-11-09 2006-06-22 Mount Sinai School Of Medicine Of New York University Treatment of cancer by simultaneous inhibiton of BRAF and restoration or mimicry of p16INK4A activity
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
BRPI0719112A2 (pt) * 2006-11-20 2013-12-10 Novartis Ag Sais e formas de cristal de 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-di-hidro-imi dazo[4,5-c]quinolin-1-il)-fenil]-propionitrila
SI2300455T1 (sl) * 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
PL2331547T3 (pl) 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
JO3002B1 (ar) * 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
KR20120097496A (ko) 2009-10-12 2012-09-04 글락소스미스클라인 엘엘씨 조합물
TWI480276B (zh) * 2010-08-27 2015-04-11 Irm Llc 作為蛋白質激酶抑制劑之化合物及組合物
BR112013012485A2 (pt) * 2010-11-19 2016-09-06 Glaxosmithkline Ip No 2 Ltd método de tratamento com inibidor braf
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
WO2012178038A1 (en) 2011-06-24 2012-12-27 The Broad Institute, Inc. Methods of treating cancer
EP2570127A1 (en) 2011-09-16 2013-03-20 Sanofi Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
SG11201400724SA (en) * 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
LT2882440T (lt) 2012-08-07 2019-04-25 Novartis Ag Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį
AU2014233805B2 (en) 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor

Also Published As

Publication number Publication date
US20160296520A1 (en) 2016-10-13
US10548894B2 (en) 2020-02-04
US9913844B2 (en) 2018-03-13
PH12015502040B1 (en) 2016-01-18
TN2015000389A1 (en) 2017-01-03
HUE055072T2 (hu) 2021-10-28
CA2907704A1 (en) 2014-09-25
IL241188A0 (en) 2015-11-30
AR095699A1 (es) 2015-11-04
PH12015502040A1 (en) 2016-01-18
TWI603734B (zh) 2017-11-01
AU2014233805B2 (en) 2018-10-18
IL272921A (en) 2020-04-30
UA118846C2 (uk) 2019-03-25
IL272921B (en) 2022-10-01
HK1214135A1 (zh) 2016-07-22
MX2015013466A (es) 2016-06-21
KR20210110794A (ko) 2021-09-09
SG10201906270VA (en) 2019-08-27
CA2907704C (en) 2023-01-10
MA38522A1 (fr) 2017-10-31
KR102446839B1 (ko) 2022-09-23
MY181085A (en) 2020-12-17
CL2018001371A1 (es) 2018-09-07
PT2976106T (pt) 2021-05-26
EP2976106A2 (en) 2016-01-27
JP6449234B2 (ja) 2019-01-09
MA44934B1 (fr) 2021-11-30
CN112641787A (zh) 2021-04-13
KR102258698B1 (ko) 2021-06-01
BR112015023483A8 (pt) 2019-12-03
CY1124776T1 (el) 2022-11-25
US20180221370A1 (en) 2018-08-09
IL272921B2 (en) 2023-02-01
IL241188B (en) 2021-02-28
GT201500249A (es) 2017-09-01
MA44934A1 (fr) 2020-01-31
ES2870716T3 (es) 2021-10-27
CN105209073A (zh) 2015-12-30
SG11201507730UA (en) 2015-10-29
PL2976106T3 (pl) 2021-10-25
US20200246338A1 (en) 2020-08-06
NZ751830A (en) 2020-09-25
BR112015023483A2 (pt) 2017-07-18
JP2016522160A (ja) 2016-07-28
BR112015023483B1 (pt) 2022-07-19
TW201440770A (zh) 2014-11-01
CL2015002807A1 (es) 2016-05-13
DK2976106T3 (da) 2021-06-14
KR20150132205A (ko) 2015-11-25
JP6742391B2 (ja) 2020-08-19
JP2019055978A (ja) 2019-04-11
ZA201800424B (en) 2022-10-26
JOP20140128B1 (ar) 2021-08-17
PE20151785A1 (es) 2015-12-20
WO2014147573A3 (en) 2014-12-11
NZ712184A (en) 2020-01-31
AU2014233805A1 (en) 2015-10-01
EP2976106B1 (en) 2021-04-14
SI2976106T1 (sl) 2021-08-31
WO2014147573A2 (en) 2014-09-25
EA201591842A1 (ru) 2016-01-29

Similar Documents

Publication Publication Date Title
BR112015023483B8 (pt) Uso de um inibidor de b-raf e um inibidor de mek 1/2"
Hofheinz et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
Blay et al. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial
Pasquier et al. Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study
Haviland et al. Radiotherapy for breast cancer, the TARGIT-A trial
BR112012020101A2 (pt) método diagnósticos e terapêuticos usando anticorpos anti-cd200.
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
BR112012022801B8 (pt) método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
BR112014024219A8 (pt) Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit
BR112017019190A2 (pt) uso de 2,3-di-hidroimidazo[1,2-c]quinazolinas substituídas
Fallahi et al. Selective use of vandetanib in the treatment of thyroid cancer
BR112015002706A8 (pt) Niclosamida e seus derivados para uso no tratamento de tumores sólidos
Sinha et al. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low‐grade B‐cell lymphomas
RU2013126036A (ru) Способ лечения опухолей
BR112014018374A8 (pt) Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
BR112019002355A2 (pt) composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme
Umemura et al. Possible macrophage activation in melanoma patients receiving combined kinase inhibitor therapy following anti-PD-1 therapy: a cytokine profiling study of two cases
Thompson et al. Bone mineral density screening should be routine in lymphoma patients
Ferraldeschi et al. A Phase 1/2 study of AT13387, a heat shock protein 90 (Hsp90) inhibitor in combination with abiraterone acetate (AA) and prednisone (P) in patients (pts) with castration-resistant prostate cancer (mCRPC) no longer responding to AA
Fıstıkçı et al. Executive functions and thyroid volumes in bipolar patients on lithium treatment
鄢曹鑫 Preoperative gross classification of gastric adenocarcinoma: Comparison of double contrast-enhanced ultrasound and multidetector row CT
Hatami et al. Evaluating the Relation of Complete Denture Quality, Oral and Psychological Condition with Patient's Satis Faction
Haviland et al. Intraoperative radiotherapy for breast cancer
Sakata et al. Questionnaire survey on medical practice for acute low-tone sensorineural hearing loss in the fukuoka area

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/03/2014, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: ARRAY BIOPHARMA INC. (US)